{"id":39661,"date":"2015-08-12T00:00:00","date_gmt":"2015-08-12T00:00:00","guid":{"rendered":"https:\/\/setterwalls.se\/case\/setterwalls-assist-allligator-bioscience-in-transaction-with-johnson-johnson\/"},"modified":"2022-02-14T13:44:57","modified_gmt":"2022-02-14T13:44:57","slug":"setterwalls-assist-allligator-bioscience-in-transaction-with-johnson-johnson","status":"publish","type":"assignments","link":"https:\/\/setterwalls.se\/en\/case\/setterwalls-assist-allligator-bioscience-in-transaction-with-johnson-johnson\/","title":{"rendered":"Setterwalls assist Allligator Bioscience in transaction with Johnson &amp; Johnson"},"content":{"rendered":"<p><strong>Alligator Bioscience AB, a privately held Swedish biotech company developing immune-oncology antibodies for directed immunotherapy of cancer, has entered into a definitive agreement with Janssen Biotech, Inc. (Janssen). Under the agreement, Janssen, will be granted an exclusive, worldwide license to Alligator Bioscience AB&#8217;s clinical candidate ADC-1013 that currently is in Phase I clinical trials. <\/strong><\/p>\n<p>Alligator Bioscience AB will receive an up-front payment plus additional contingent payments upon reaching certain pre-determined milestones up to a potential total of US$700 million. Alligator Bioscience AB is also eligible to receive royalties on worldwide net sales upon successful launch and commercialization. In a simultaneous transaction, Johnson &amp; Johnson Innovation &#8211; JJDC, Inc. will subscribe for new shares in Alligator Bioscience AB. The closing of the transaction is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act.<\/p>\n","protected":false},"excerpt":{"rendered":"<p><strong>Alligator Bioscience AB, a privately held Swedish biotech company developing immune-oncology antibodies for directed immunotherapy of cancer, has entered into a definitive agreement with Janssen Biotech, Inc. (Janssen). Under the agreement, Janssen, will be granted an exclusive, worldwide license to Alligator Bioscience AB&#8217;s clinical candidate ADC-1013 that currently is in Phase I clinical trials. <\/strong><\/p>\n<p>Alligator Bioscience AB will receive an up-front payment plus additional contingent payments upon reaching certain pre-determined milestones up to a potential total of US$700 million. Alligator Bioscience AB is also eligible to receive royalties on worldwide net sales upon successful launch and commercialization. In a simultaneous transaction, Johnson &amp; Johnson Innovation &#8211; JJDC, Inc. will subscribe for new shares in Alligator Bioscience AB. The closing of the transaction is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act.<\/p>\n","protected":false},"author":1,"featured_media":34236,"template":"","meta":{"_acf_changed":false,"_seopress_robots_primary_cat":"","_seopress_titles_title":"","_seopress_titles_desc":"","_seopress_robots_index":""},"class_list":["post-39661","assignments","type-assignments","status-publish","has-post-thumbnail","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/setterwalls.se\/en\/wp-json\/wp\/v2\/assignments\/39661","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/setterwalls.se\/en\/wp-json\/wp\/v2\/assignments"}],"about":[{"href":"https:\/\/setterwalls.se\/en\/wp-json\/wp\/v2\/types\/assignments"}],"author":[{"embeddable":true,"href":"https:\/\/setterwalls.se\/en\/wp-json\/wp\/v2\/users\/1"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/setterwalls.se\/en\/wp-json\/wp\/v2\/media\/34236"}],"wp:attachment":[{"href":"https:\/\/setterwalls.se\/en\/wp-json\/wp\/v2\/media?parent=39661"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}